Stereotaxis (NYSE American: STXS) Q2 2026 revenue slips to $7.7M as losses widen and cash hits $10.5M
Rhea-AI Filing Summary
Stereotaxis, Inc. reported 2026 second quarter results with total revenue of $7.7 million for the quarter ended June 30, 2026, compared with $8.8 million a year earlier. System revenue was $1.5 million, down from $3.0 million in the prior-year quarter, reflecting the absence of a robotic system delivery, partially offset by initial Synchrony digital operating room sales. Recurring revenue from disposables, service, and accessories was $6.2 million, up from $5.8 million, supported by new robotic catheter contributions.
Gross margin was 58% of revenue. Operating expenses were $9.1 million, including $2.5 million of non-cash items, resulting in an operating loss of ($4.6) million and a net loss of ($4.5) million, compared with ($3.8) million a year earlier. Cash and cash equivalents were $10.5 million with no debt at June 30, 2026, and negative free cash flow was ($3.7) million.
The company highlighted that robotic catheter revenue surpassed $1 million with 270% sequential growth, reported the first U.S. GenesisX system purchase, multiple Synchrony installations following April FDA clearance, and completion of the Robocath acquisition. Management expects recurring revenue of approximately $7 million in the third quarter and $8 million in the fourth quarter, system revenue of about $3 million in each quarter, and anticipates reaching cash flow profitability in the first half of 2027.
Positive
- Robotic catheter revenue exceeded $1M with 270% sequential growth, signaling early commercial traction for new products despite overall revenue decline.
- Completion of the Robocath acquisition expands Stereotaxis’ robotic technology across endovascular procedures and supports its strategy to grow without substantial investor dilution.
- Guidance calls for rising recurring revenue to ~$7M in Q3 and ~$8M in Q4 2026, with system revenue of about $3M per quarter and targeted cash flow profitability in the first half of 2027.
Negative
- Quarterly revenue declined to $7.7M from $8.8M year over year, driven by a sharp drop in system revenue due to no robotic system delivery.
- Net loss widened to $4.5M from $3.8M in the prior-year quarter, with negative free cash flow of $3.7M and a cash balance of $10.5M limiting liquidity headroom.
Filing Explained
The July 15 resale registration is ineffective with no recorded usage, creating conversion and resale capacity rather than a completed issuance.
Stereotaxis says it can pursue its strategy without substantial dilution, but the
Management’s dilution statement is therefore qualified by the S-3’s mechanics: up to 72,722,177 shares are issuable upon preferred-stock conversion and 36,146,154 shares were issued upon related warrant exercise.
A private placement is a sale to selected investors outside a public offering, with resale commonly requiring later registration; here, the company says it will not sell securities or receive proceeds from these resales, and the conversion amount is a ceiling rather than an amount issued.
The named follow-up is the S-3’s status and usage: the supplied shelf record lists expiration on
8-K Event Classification
Key Figures
Key Terms
recurring revenue financial
free cash flow financial
contingent consideration financial
convertible preferred stock financial
deferred revenue financial
cash flow profitability financial
Earnings Snapshot
Company expects recurring revenue of approximately $7M in Q3 2026 and $8M in Q4 2026, system revenue of about $3M in each of those quarters, and anticipates reaching cash flow profitability in the first half of 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How much revenue did Stereotaxis (STXS) report for Q2 2026?
What were Stereotaxis (STXS) profits or losses in Q2 2026?
What is Stereotaxis’ (STXS) cash position and debt level as of June 30, 2026?
What financial guidance did Stereotaxis (STXS) provide for the rest of 2026?
What strategic milestones did Stereotaxis (STXS) highlight in Q2 2026?
How did Stereotaxis (STXS) gross margin and operating expenses trend in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
| (Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act: ☐
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Item 2.02 | Results of Operations and Financial Condition |
On August 11, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Forward-Looking Statements and Additional Information
Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
| 99.1 | Stereotaxis, Inc. Earnings Press Release dated August 11, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STEREOTAXIS, INC. | ||
| Date: August 11, 2026 | By: | /s/ Kimberly R. Peery |
| Name: | Kimberly R. Peery | |
| Title: | Chief Financial Officer | |
Exhibit 99.1
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
| ● | Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially | |
| ● | First GenesisX robotic system purchase by US hospital to be installed this fall | |
| ● | Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April | |
| ● | Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures |
St. Louis, MO, August 11, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
“Stereotaxis has reached an important commercial inflection point. Following years of product development and regulatory milestones, the Company’s expanded robotic platform is now generating accelerating commercial adoption across multiple product lines,” said David Fischel, Stereotaxis Chairman and CEO. “Over the last several years we advanced an exciting ecosystem of robotic, catheter and digital innovations through development and regulatory milestones. We are now witnessing the initial green shoots of commercial success, including quarterly revenue from our novel robotic catheters exceeding one million dollars, the first Synchrony system sales, and the first US purchase of a GenesisX robot.”
“We are making methodical progress on the operational and commercial efforts needed to drive revenue growth. We expect continued momentum throughout this year as we ramp manufacturing and address commercial friction. We have line of sight to sustained revenue growth and reaching cash flow profitability in the coming quarters.”
“In parallel to our commercial efforts, we continue to invest in a broad pipeline of innovations that expand our technology into a platform across endovascular surgery, enhances our competitiveness in electrophysiology, and delivers digital connectivity, automation and intelligence to the operating room.”
2026 Second Quarter Financial Results
Revenue for the second quarter of 2026 totaled $7.7 million. System revenue of $1.5 million declined from $3.0 million in the prior year second quarter, with the lack of a robotic system delivery in the quarter partially countered by initial Synchrony sales. Recurring revenue of $6.2 million increased from $5.8 million in the prior year second quarter, reflecting contributions from Stereotaxis’ new robotic catheters counteracting general procedural pressure from limited catheter supply.
Gross margin for the second quarter of 2026 was 58% of revenue. Recurring revenue gross margin was 66%, and system gross margin was 29%. Operating expenses in the quarter of $9.1 million included $2.5 million in non-cash charges for stock compensation expense, mark-to-market adjustment for acquisition related contingent earnout consideration, and amortization of acquired intangible assets. Excluding these non-cash charges, adjusted operating expenses were $6.6 million, consistent with the year-ago period when adjusting for a one-time employee retention tax credit received in the prior year.
Operating loss and net loss in the second quarter of 2026 were ($4.6) million and ($4.5) million, respectively, compared with ($4.0) million and ($3.8) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were ($2.1) million and ($2.0) million, respectively, compared with ($1.4) million and ($1.3) million in the previous year quarter. Negative free cash flow for the second quarter was ($3.7) million, consistent with the previous year.
Cash Balance and Liquidity
At June 30, 2026, Stereotaxis had cash and cash equivalents of $10.5 million and no debt.
Forward Looking Expectations
Stereotaxis anticipates recurring revenue to grow to approximately $7 million in the third quarter and $8 million in the fourth quarter of this year, driven by methodical increases in MAGiC catheter manufacturing. System revenue is expected to be approximately $3 million in each of the third and fourth quarters.
Stereotaxis believes it can advance its strategy, integrate Robocath, and grow revenue significantly without having to subject investors to substantial dilution. Cash flow profitability is anticipated to be reached in the first half of 2027.
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, August 11, 2026, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 4404741. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This
press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”,
“estimate”, “project”, “expect” or similar expressions. These forward-looking statements include
without limitation statements regarding the recently completed acquisition of Robocath,
By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Additional information will also be set forth in future filings that we make with the SEC from time to time. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
Stereotaxis, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| (in thousands, except share and per share amounts) | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Systems | $ | 1,479 | $ | 3,038 | $ | 2,798 | $ | 5,002 | ||||||||
| Disposables, service and accessories | 6,191 | 5,760 | 11,163 | 11,268 | ||||||||||||
| Total revenue | 7,670 | 8,798 | 13,961 | 16,270 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Systems | 1,057 | 2,366 | 1,861 | 4,033 | ||||||||||||
| Disposables, service and accessories | 2,127 | 1,853 | 3,820 | 3,594 | ||||||||||||
| Total cost of revenue | 3,184 | 4,219 | 5,681 | 7,627 | ||||||||||||
| Gross margin | 4,486 | 4,579 | 8,280 | 8,643 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 2,390 | 1,777 | 4,787 | 4,127 | ||||||||||||
| Sales and marketing | 2,595 | 3,269 | 5,212 | 6,417 | ||||||||||||
| General and administrative | 4,069 | 4,002 | 8,830 | 8,497 | ||||||||||||
| Other | - | (492 | ) | - | (492 | ) | ||||||||||
| Total operating expenses | 9,054 | 8,556 | 18,829 | 18,549 | ||||||||||||
| Operating loss | (4,568 | ) | (3,977 | ) | (10,549 | ) | (9,906 | ) | ||||||||
| Other income | - | (1 | ) | (5 | ) | (1 | ) | |||||||||
| Interest income, net | 100 | 152 | 225 | 258 | ||||||||||||
| Net loss | $ | (4,468 | ) | $ | (3,826 | ) | $ | (10,329 | ) | $ | (9,649 | ) | ||||
| Cumulative dividend on convertible preferred stock | (314 | ) | (318 | ) | (625 | ) | (632 | ) | ||||||||
| Net loss attributable to common stockholders | $ | (4,782 | ) | $ | (4,144 | ) | $ | (10,954 | ) | $ | (10,281 | ) | ||||
| Net loss per share attributed to common stockholders: | ||||||||||||||||
| Basic | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.11 | ) | $ | (0.12 | ) | ||||
| Diluted | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.11 | ) | $ | (0.12 | ) | ||||
| Weighted average number of common shares and equivalents: | ||||||||||||||||
| Basic | 100,031,760 | 87,952,086 | 99,496,942 | 87,861,231 | ||||||||||||
| Diluted | 100,031,760 | 87,952,086 | 99,496,942 | 87,861,231 | ||||||||||||
STEREOTAXIS, INC.
CONSOLIDATED BALANCE SHEETS
| (in thousands, except share amounts) | June 30, 2026 | December 31, 2025 | ||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 10,491 | $ | 13,421 | ||||
| Accounts receivable, net of allowance of $594 and $541 at 2026 and 2025, respectively | 7,549 | 5,847 | ||||||
| Insurance receivable | 6,316 | 4,316 | ||||||
| Inventories, net | 12,520 | 9,567 | ||||||
| Prepaid expenses and other current assets | 1,111 | 698 | ||||||
| Total current assets | 37,987 | 33,849 | ||||||
| Property and equipment, net | 2,881 | 3,019 | ||||||
| Goodwill | 3,764 | 3,764 | ||||||
| Intangible assets, net | 5,957 | 6,429 | ||||||
| Operating lease right-of-use assets | 4,658 | 4,912 | ||||||
| Prepaid and other non-current assets | 335 | 278 | ||||||
| Total assets | $ | 55,582 | $ | 52,251 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 6,866 | $ | 4,768 | ||||
| Accrued liabilities | 1,325 | 2,065 | ||||||
| Accrued legal liabilities | 6,316 | 4,316 | ||||||
| Deferred revenue | 5,928 | 5,675 | ||||||
| Current contingent consideration | 5,673 | 4,894 | ||||||
| Current portion of operating lease liabilities | 689 | 642 | ||||||
| Total current liabilities | 26,797 | 22,360 | ||||||
| Long-term deferred revenue | 384 | 555 | ||||||
| Long-term contingent consideration | 5,343 | 4,724 | ||||||
| Operating lease liabilities | 4,484 | 4,794 | ||||||
| Other liabilities | 1,097 | 1,097 | ||||||
| Total liabilities | 38,105 | 33,530 | ||||||
| Series A - Convertible preferred stock: | ||||||||
| Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 20,983 and 21,008 shares outstanding at 2026 and 2025, respectively | 5,234 | 5,240 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock, par value $0.001; 300,000,000 shares authorized, 97,938,091 and 95,339,628 shares issued at 2026 and 2025, respectively | 98 | 95 | ||||||
| Additional paid-in capital | 606,048 | 596,960 | ||||||
| Treasury stock, 4,015 shares at 2026 and 2025 | (206 | ) | (206 | ) | ||||
| Accumulated deficit | (593,697 | ) | (583,368 | ) | ||||
| Total stockholders’ equity | 12,243 | 13,481 | ||||||
| Total liabilities and stockholders’ equity | $ | 55,582 | $ | 52,251 | ||||